Shots:

• The P-III (DELIVER) trial evaluates the efficacy of Farxiga (qd) vs PBO in patients with HFpEF with LVEF ≥40% with/out T2D
• The results showed a reduction in the primary composite EPs of CV death or worsening HF, safety & tolerability were consistent with the well-established safety profile of the therapy. The results will be submitted for presentation at a medical meeting and regulatory submissions are expected in the coming mos.
• Farxiga was effective in treating HF regardless of ejection fraction. The 2EPs include total number of HF events &  CV death, change from baseline in the total symptom score of  KCCQ @8mos., time to the occurrence of CV death & death from any cause

Ref: Businesswire | Image: AstraZeneca